NCT03395080: A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma |
|
|
| Completed | 2 | 111 | US | Paclitaxel, Taxol, 300mg DKN-01, 600mg DKN-01 | Leap Therapeutics, Inc. | Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma | 09/20 | 01/21 | | |
